| Author, Year Quality | Condition Number Enrolled | Comparison Duration of Study | Main Results |
|---|---|---|---|
| Glucosamine Trials | |||
| Herrero-Beaumont, 2007204 Fair | OA of knee 318 | Glucosamine sulfate 1500 mg powder for oral solution qd Acetaminophen 1 gm po tid Placebo 6 months | Glucosamine sulfate vs. acetaminophen vs. placebo Change from baseline: Lequesne Index (0 to 24): −3.1 vs. −2.7 vs. −1.9; p=0.032 for difference vs. placebo WOMAC total (0 to 100): −12.9 vs. −12.3 vs. −8.2; p=0.039 for difference vs. placebo WOMAC pain (0 to 100): −2.7 vs. −2.4 vs. −1.8; NS WOMAC function (0 to 100): −9.2 vs. −8.7 vs. −5.5; p=0.022 for difference vs. placebo OARSI-A responders: 40% vs. 21.2% for placebo, p= 0.004 |
| Rozendaal, 2008205 Rozendaal, 2009 Good | OA of hip 222 | Glucosamine sulfate 1500 mg po qd or bid Placebo 24 months | Glucosamine sulfate vs. placebo Change from baseline: WOMAC pain (0 to 100): −1.90 ± 1.6 vs. −0.30 ± 1.6, adjusted difference −1.54 (−5.43 to 2.36) WOMAC function (0 to 100): −1.69 ± 1.3 vs. 0.38 ± 1.3, adjusted difference −2.01 (95% CI −5.38 to 1.36) JSN, mm adjusted difference: Minimal: −0.029 (95% CI −0.122 to 0.064) Lateral: −0.017 (95% CI −0.121 to 0.088) Superior: 0.016 (95% CI −0.079 to 0.111) Axial: −0.005 (95% CI −0.118 to 0.108) |
| Wilkens, 2010206 Good | Degenerative lumbar OA 250 | Glucosamine sulfate 1500 mg po qd or tid Placebo 6 months | Glucosamine sulfate vs. placebo Treatment Effect at 1 year (negative values favor glucosamine): RMDQ (0 to 24): −0.8 (95% CI −2.0 to 0.4), p=0.50 NRS LBP (0 to 10): −0.3 (95% CI −0.8 to 0.3). p=.85 Global perceived effect, No. (%):* 34 (30.9%) vs. 32 (29.4%), p=.30 |
| Chondroitin Trials | |||
| Kahan, 2009207 Fair | OA of knee 622 | Chondroitin sulfates 4 & 6 800 mg every evening Placebo 2 years | Chondroitin sulfate vs. placebo At 6 months: WOMAC pain score decrease ≥40%: 41% vs. 34%, p=0.05 No difference in WOMAC total, stiffness, or function At 24 months: minimum JSW loss (mean ± SEM): −0.07 ± 0.03 mm vs. −0.31 ± 0.04 mm Hodges-Lehmann estimator of median effect of treatment: −0.14 (95% CI 0.06 – 0.21 mm, p<0.0001) |
| Mazieres, 2010208 Fair | OA of knee 307 | Chondroitin sulfate 500 mg po bid Placebo 24 weeks | Chondroitin sulfate vs. placebo Change from baseline to week 24, M (SD): Lequesne Index, (0 to 24): −2.4 (3.4) vs. −1.7 (3.3), p=0.109 VAS pain, mm: −26.2 (24.9) mm vs. −19.9 (23.5) mm, p= 0.029 OMERACT-OARSI responders: 68% vs. 56% (p=0.03) |
| Michel, 2005209 Fair | OA of knee 300 | Chondroitin sulfates 4 & 6 800 mg po qd Placebo 2 years | Chondroitin sulfate vs. placebo Changes in WOMAC: Total: −3.9% vs. 2.1% Pain: −11.0% vs. −6.2% Stiffness: −7.8% vs. −4.6% Function: −0.8% vs. 5.9% JSN Minimum difference: 0.12 (95% CI 0.00 to 0.24), p=0.05 JSM Mean difference: 0.14 (95% CI 0.01 to 0.27), p =0.04 |
| Moller, 2010210 Fair | OA of knee (in patients with psoriasis) 129 | Chondroitin sulfate 800 mg po qd Placebo 3 months | Chondroitin sulfate vs. placebo (mean differences at 3 months) Pain intensity (0 to 100 mm VAS): −12 (95% CI −20 to −4) Lequesne Index (0 to 24): −1.7 (95% CI −3.0 to −0.4) SF-36 physical component (0 to 100): 1.7 (95% CI 1.4 to −1.2) SF-36 mental component (0 to 100): −0.3 (95% CI −3.3 to 2.6) |
| Glucosamine/Chondroitin Trials | |||
| Messier, 2007211 Fair | OA of knee 89 | Glucosamine hydrochloride 1500 mg and Chondroitin sulfate 1200 mg qd or tid Placebo 1 year; 6 months alone; 6 months treatment plus exercise | Glucosamine hydrochloride + chondroitin sulfate vs. placebo At 12 months: WOMAC pain (0 to 20): 6.0 (0.5) vs. 5.18 (0.5) WOMAC function (0 to 68): 19.4 (1.2) vs. 20.6 (1.2)b |
| Sawitzke, 2008212 Good | OA of knee 662 | Glucosamine sulfate 500 mg tid Chondroitin sulfate 400 mg tid Combination of Glucosamine and Chondroitin Celecoxib 200 mg qd Placebo 24 months | Glucosamine hydrochloride vs. chondroitin sulfate vs. both vs. placebo Mean loss in JSW over 2 years: 0.013 vs. 0.107 vs. 0.194 vs. 0.111 vs. 1.166 Difference from placebo (negative value = less JSW loss): −0.153 (−0.379, 0.074) vs. −0.059 (−0.287, 0.169) vs. 0.028 (−0.214,0.271) vs. −0.055 (−0.279, 0.170) Disease progression over 2 years, % of patients:18.6 vs. 21.4 vs. 24.4 vs. 20.2 vs. 22.4 |
bid = twice daily; JSM = joint space measurement; JSN = joint space narrowing; JSW = joint space width; NRS LBP = numerical rating scale for low back pain; OA = osteoarthritis; OMERACT-OARSI = Outcomes Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International; po = orally; RMDQ = Roland Morris Disability Questionnaire; qd = once daily; qid = four time daily; tid = three times daily; VAS = visual analogue scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index
Proportion of patients who had a global perceived effect to the intervention
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.